Table 4.
Patient characteristics of the included trials
| Study ID | Interventions | Mean age | Males – n (%) | AIDS-defining illness – n (%) | Baseline CD4 (cells/mm3) mean | Baseline viral load (log copies/mL) mean | Men who have sex w/ men – n (%) | Persons who inject drugs – n (%) |
|---|---|---|---|---|---|---|---|---|
| ACTG A5073 [12] | SOC | 39.3 | 127 (79) | – | 233 | 4.8 | – | 18 (12) |
| Supporter | 38 | 65 (79) | – | 212 | 5 | – | 10 (12) | |
| ACTG a5234 [13] | SOC | 37a | 63 (49) | – | 201a | 4.3a | – | – |
| Supporter | 38a | 67 (52) | – | 164a | 4.2a | – | – | |
| Altice et al. [14] | SOC | 44.9a | 37 (69.8) | – | 384a | 2.8a | – | 35 (66) |
| Treatment supporter | 42.7a | 60 (68.2) | – | 283a | 3.8a | – | 57 (64.8) | |
| ATHENA [15] | SOC | – | 40 (48) | – | 415 | 4.47 | – | 6 (8) |
| Peer supporter | – | 48 (55) | – | 445 | 4.46 | – | 3 (4) | |
| Berrien et al. [16] | SOC | 11.2 | 9 (55) | – | 860.8 | 3.92 | – | – |
| Treatment supporter | 9.9 | 9 (45) | – | 838.6 | 3.67 | – | – | |
| SOC | 36 | 19 (54.3) | – | 194 | 5.75 | 2 | – | |
| Goggin et al. [17] | CBT+Treatment supporter | 40.4 | 50 (76.9) | – | – | 4.2a | – | 29 (42) |
| CBT | 40.8 | 50 (71.4) | – | – | 4.3a | – | 30 (43.5) | |
| eSOC | 39.9 | 55 (79.7) | – | – | 5 | – | 29 (44.6) | |
| Kiweewa et al. [18] | Treatment supporter | 27.8 | 0 (0) | – | 204a | 4.5a | – | – |
| SOC | 27 | 0 (0) | – | 201a | 4.8a | – | – | |
| Lucas et al. [19] | Treatment supporter | 47a | 25 (48) | – | – | 4.97 | – | 26 (50) |
| SOC | 47a | 31 (56) | – | – | 4.78 | – | 22 (40) | |
| Macalino et al. [20] | Treatment supporter | 41.7 | 34 (79) | – | – | – | – | 33 (76.7) |
| SOC | 43.1 | 27 (61) | – | – | – | – | 39 (88.6) | |
| Mugusi et al. [21] | eSOC | 39.9 | 96 (31) | 7 (2.3) | 98.1 | – | – | – |
| Supporter | – | 0 (0) | – | – | – | – | – | |
| CBT+Device reminder | 39.5 | 94 (39) | 6 (2.5) | 97.7 | – | – | – | |
| CBT+Peer supporter | 37.8 | 28 (42) | 2 (3) | 91.1 | – | – | – | |
| Nachega et al. [22] | SOC | 36.7 | 58 (42.3) | 61 (44.5) | 103a | 5a | – | – |
| Treatment supporter | 35.7 | 58 (42.3) | 65 (47.4) | 92a | 5a | – | – | |
| Pearson et al. [23] | eSOC | 36.1 | 82 (46.9) | – | – | – | – | – |
| Peer supporter | 35.6 | 80 (45.7) | – | – | – | – | – | |
| Rakai Health Sciences Program [24] | SOC | 34a | 119 (32.5) | – | 161a | – | – | – |
| Peer supporter | 35.5a | 332 (34.2) | – | 160a | – | – | – | |
| Remien et al. [25] (SMART Couples Study) | SOC | – | – | – | – | 4.05 | – | – |
| Peer supporter | – | – | – | – | 4.20 | – | – | |
| Ruiz et al. [26] | Peer supporter | 41.32 | 81 (67.5) | – | 471 | – | 33 (28) | 51 (42.5) |
| CBT | 41 | 95 (79) | – | 486 | – | 24 (20.5) | 59 (49.2) | |
| Simoni et al. [27] | SOC | 42.5 | 40 (62.5) | – | – | 8.4 | – | 35 (53.8) |
| Peer supporter | 42.6 | 35 (49.3) | – | – | 8 | – | 35 (49.3) | |
| Simoni et al. [28] | SOC | – | – | – | 198.5 | 4.3 | – | – |
| Peer supporter | – | – | – | 195.4 | 4.3 | – | – | |
| Device reminder | – | – | – | 229.2 | 4.6 | – | – | |
| Peer supporter+Device reminder | – | – | – | 194.3 | 4.5 | – | – | |
| START-DOT [29] | SOC | 49 | 22 (58) | – | 277a | 2.89 | – | – |
| Treatment supporter | 45 | 19 (49) | – | 367a | 2.74 | – | – | |
| Taiwo et al. [30] | SOC | – | 83 (33.5) | – | 107.6 | 4.82a | – | – |
| Treatment supporter | – | 91 (36.3) | – | 106.1 | 4.78a | – | – | |
| Wang et al. [31] | SOC | 36.7 | 49 (84) | – | – | – | – | 58 (100) |
| Treatment supporter+Telephone | 36.7 | 49 (84) | – | – | – | – | 58 (100) | |
| Williams et al. [32] | SOC | 37 | 42 (76.4) | – | 137 | – | – | 21 (38.2) |
| Peer supporter+Telephone | 38 | 36 (65.5) | – | 149 | – | – | 14 (25.5) | |
| Wohl et al. [33] | SOC | – | 66 (78.6) | – | 143a | 4.2a | 29 (34.5) | 4 (4.8) |
| Treatment supporter | – | 59 (72) | – | 105a | 4.6a | 25 (30.5) | 5 (6.1) |
a
Median value reported.